+17%

est. 2Y upside i

Healthcare

The smart testing platform that unlocks digital health at home.

Rank

#3039

Sector

Health Diagnostics

Est. Liquidity

~6Y

Data Quality

Data: Low

Scout is a high-risk, pre-commercial bet: 12 employees, no disclosed revenue or valuation, and the most recent $6M financing is a non-dilutive government grant rather than an equity round that would price the company.

Last updated: May 13, 2026

Bull (15%)+250%

Scout achieves FDA clearance across 2+ indications including gonorrhea and respiratory pathogens, wins enterprise health system contracts beyond Medcor, and attracts acquisition by Abbott, Roche, or Danaher at $400–600M to integrate its portable molecular platform. Common stockholders realize roughly 250% upside after liquidation preferences on an estimated $40–50M entry valuation.

Base (45%)+30%

Scout clears FDA for one indication, raises a Series A equity round at a modest step-up, but commercialization lags due to incumbent distribution advantages and capital constraints. A strategic acquisition at ~$100–150M in 6–8 years delivers approximately 30% upside to employee common stock after preference liquidation and two rounds of dilution.

Bear (40%)-85%

FDA clearance delays or rejection exhausts Scout's runway before commercial revenue is established, and equity markets prove unreceptive to a 12-person pre-revenue diagnostics startup with dominant incumbents already in market. Common equity is nearly wiped out as preferred liquidation preferences consume substantially all remaining asset value in a wind-down or distressed sale.

Est. time to liquidity~6.0 years

Preference Stack Risk

high

Funding Intensity

51%

With $23M in cumulative funding (a portion non-dilutive grants) and no disclosed valuation, estimated effective equity preference represents 20–35% of any exit enterprise value — firmly in high-risk territory for common stockholders.

Dilution Risk

high

At 12 employees and pre-revenue stage, Scout will require at least two additional equity financing rounds (Series A and B) to fund regulatory, manufacturing, and commercial build-out, implying 40–60% dilution to current option holders.

Secondary Liquidity

none

No secondary market activity is plausible for a 12-person pre-revenue diagnostics startup; employee equity will be fully illiquid until a strategic acquisition or a highly unlikely IPO.

Questions to Ask at the Interview

Strategic questions based on Scout's data — designed to show you've done your homework.

  • 1

    “What is the specific FDA regulatory pathway and submission timeline for your first commercially cleared indication, and how many months of runway does current funding provide to reach that milestone?”

  • 2

    “How does Scout plan to transition from CARB-X grant dependency to equity financing or self-sustaining commercial revenue, and what does the customer pipeline beyond Medcor look like today?”

  • 3

    “What is the current fully diluted share count and option pool percentage, and how do you model cap table dilution through the Series A and B rounds needed to reach commercial scale?”

Community

Valuation Sentiment

Our model estimates +17% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.